 | | Vol. 13.06 – 15 February, 2024 |
| |
|
|
| The Phase II umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following the failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy.
[Nature Medicine] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators reported a clinical trial of intrapulmonary P63+ progenitor cell transplantation in 28 participants with stage II to IV COPD.
[Science Translational Medicine] |
|
|
|
| Investgiators compared positive end-expiratory pressure targeting either minimal overdistention, minimal collapse or using a compromise between collapse and overdistention in a randomized trial, and assess the impact on respiratory mechanics, gas exchange, inflammation, and hemodynamics.
[American Journal Of Respiratory And Critical Care Medicine] |
|
|
|
| Scientists found that H2O2 induced an elevation in [Cl−]i by modulating the expression of cystic fibrosis transmembrane conductance regulator (CFTR) and Ca-activated transmembrane protein 16 A in airway epithelial cells, whereas lipopolysaccharide achieved this solely through CFTR.
[Respiratory Physiology & Neurobiology] |
|
|
|
| Researchers investigated the role and mechanisms of praziquantel in pulmonary fibrosis in a murine model induced by bleomycin.
[BMC Pharmacology & Toxicology] |
| |
|
|
| The Phase II umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following the failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy.
[Nature Medicine] |
|
|
|
| Scientists uncovered SET-associated transcription factor, zinc finger, and BTB domain-containing protein 11 (ZBTB11), as a prometastatic regulator in lung tumors.
[Nature Communications] |
|
|
|
| Researchers assessed the preclinical efficacy of BI-4732, a novel fourth-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, using patient-derived preclinical models reflecting various clinical scenarios.
[Clinical Cancer Research] |
|
|
|
| Investigators systematically explored the validity of sequential ALK inhibitors for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models.
[Acta Pharmacologica Sinica] |
|
|
|
| The effects of prophylactic pegfilgrastim on febrile neutropenia prevention, therapeutic efficacy, and prognosis after ramucirumab plus docetaxel were evaluated in patients with advanced NSCLC.
[Scientific Reports] |
|
|
|
|
| The authors describe the relevant anatomy of the upper airway and discuss the literature detailing the identification and roles of the progenitor cells of these regions.
[Cells & Development] |
|
|
|
| | Krystal Biotech, Inc. announced that the US FDA has granted Fast Track Designation for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard-of-care therapy.
[Krystal Biotech, Inc.] |
|
|
|
|
| March 3 – 8, 2023
Ventura, California, United States |
|
|
|
|
|
| | University of Kentucky – Lexington, Kentucky, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | Queens University Belfast – Belfast, Ireland, United Kingdom |
|
|
|
| | Cyprus Cancer Research Institute – Aglandjia, Cyprus |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
